Upcoming webinar

Maximizing ROI: Extracting value from analysis and reporting

June 18, 2024
8:00 AM PDT | 11:00 AM EDT | 4:00 PM BST

Digital Maturity Webinar Series
Session 5

Step towards a robust and adaptive lab of the future

While dreams of transformative analytics frequent the minds of many in the BioPharma world, the reality is quite jarring. Many organizations find themselves in “pilot purgatory” when looking to implement initiatives to drive optimization via digitalization and advanced analytics. As dead-end data is abandoned on islands of instrumentation and automation, these organizations quickly find that digital collection is much easier than digital connection. From our earlier webinars, we’ve seen that without the appropriate data foundations, digital tools, or digital transformational strategies in place, organizations will inevitably fall short on their digital maturity journey, hampering any endeavors to truly transform their operations.

In the concluding webinar of our Digital Maturity series, we’ll examine how data can be harnessed and utilized without sacrificing data integrity, how insights can inform and simplify subsequent process steps and decisions, and how FTEs (of all backgrounds) can be empowered to make smarter decisions faster, and thus more available to focus on the next transformative project or therapeutic.

Watch the teaser below!

Key learnings

  • How organizations can maintain data integrity when assimilating their data for meaningful insights
  • The value and impact of versatile and easy-to-use analytical tools for on-going decision-making, leading to accelerated business operations
  • How organizations can establish the foundation for advanced analytics, AI and ML, in pursuit of a robust and adaptive lab of the future
Register Now!More webinars in the series

Meet our speaker

Michael Barnes

Lead Solutions Consultant, IDBS

As a Lead Solutions Consultant for IDBS, Michael brings a wealth of knowledge and insights to successfully implement data management solutions for high-profile biopharmaceutical and biotechnology companies. By leveraging his experience and utilizing cross-functional collaborations across IDBS and Danaher, Michael looks to generate the maximum business benefit to meet customer-specific requirements and manage partner relationships on a short/long term basis.

Prior to shifting to IDBS, he worked in Pfizer’s BioProcess R&D Cell Line Development group, working to evaluate different vectors/expression systems and investigate phenotypic changes at a genotypic level, to develop a robust and cost-effective biologics platform.

Michael holds an MSc in Biomedical Engineering and Biotechnology from the University of Massachusetts-Lowell.

Discover the series